A drug delivery system for oral administration is provided. The drug delivery system includes an oral delivery carrier and a plurality of micelles attached to or dispersed in the oral delivery carrier. Each of the micelles includes a hydrophobic core and a hydrophilic corona targeted to a subject's kidney. A pharmaceutical payload is carried by the plurality of micelles.

Another drug delivery system includes a plurality of micelles and a payload within each micelle. Each micelle has a kidney targeting peptide conjugated thereto with a polyethylene glycol linking group having a molecular weight less than 1800 Daltons.

This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of T.sub.R1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.

The present disclosure provides a method for the treatment or prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in a cancer patient treated with, or to be treated with, a CIPN causing chemotherapeutic agent, the method comprising: administering a therapeutically effective amount of a composition containing a peptide amphiphile lipid micelle (PALM) nanoparticle to the cancer patient, the PALM nanoparticle comprising a PALM containing the CIPN causing chemotherapeutic agent, and wherein the PALM comprises a peptide, and a lipid component comprising sphingomyelin and one or more additional phospholipids.

The present disclosure includes compositions and methods of making a nanoparticle composition comprising a phospholipids core comprising one or more lipids and one or more active agents, and at least one layer of one or more polymers on the surface of the phospholipids core; more specifically, the disclosure relates to the use of capecitabine (N4-pentyloxycarbonyl-5-deoxy-5-fluoro-cytidine, CAP) within such a lipid-polymer nanoparticle formulation for optimizing pharmaceutical properties of capecitabine for the treatment of cancer.

Only limited success has been previously achieved from cancer vaccines targeting unmodified tumor-associated self-antigens and new compositions and methods are needed. Immunogenic compositions and methods of use thereof are provided according to the present disclosure which include a protein effective to stimulate immune activity against a tumor-associated self-antigen, or a variant thereof which is a tumor-associated self-antigen.

This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of T.sub.R1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.

Provided herein are compounds that inhibit a binding interaction between a integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

The present invention relates to reverse-micellar systems comprising at least an active agent, an acylglycerol, a sterol, lecithin, ethanol and water, for use in chelation and/or sequestering of a radionuclide and/or a metal in a patient. The invention also relates to the reverse-micellar systems and to pharmaceutical compositions comprising said reverse-micellar systems.

A polymeric compound is disclosed herein, having the general formula I:

##STR00001##

wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

Disclosed herein are compositions and nanoconjugates comprising a micelle construct; an antibody single chain fragment variable (scFv); a NF-kb inhibitor; and a topoisomerase II inhibitor. Further disclosed herein are methods of delivering a drug molecule to a tumor site of a subject comprising: attaching the drug molecule to a targeted micelle, wherein the targeted micelle comprises a micelle construct and an antibody single chain fragment variable (scFv); and delivering the drug molecule attached to the targeted micelle to the tumor site through intracellular delivery. Also disclosed herein are methods of treating cancer or inhibiting tumor cell growth comprising administering to a subject in need thereof, a therapeutically effective dosage of a composition comprising a micelle construct, an antibody single chain fragment variable (say), a NF-kb inhibitor, and a topoisomerase II inhibitor.